W
bioLLM/wiki

AI-Curated Biomedical Knowledge Base

Live
Back to List ViewGraph View

intravitreal rituximab

Overview

Intravitreal rituximab is an ophthalmic use of rituximab, a monoclonal anti-CD20 antibody, administered by injection into the vitreous cavity of the eye. In this setting, it is used as a local therapy to deliver B-cell–directed treatment directly to intraocular disease sites, rather than through systemic administration. Its principal biomedical relevance is in ocular conditions in which B-cell malignancy or immune-mediated pathology is present within the eye, especially vitreoretinal lymphoma.

As a localized route of administration, intravitreal rituximab is intended to achieve therapeutic exposure in ocular tissues while limiting systemic effects. In recent literature, it has been studied mainly as a salvage or adjunctive treatment in relapsed vitreoretinal lymphoma, including cases occurring after prior ocular radiotherapy.

Recent Publications Summary

Recent publications on intravitreal rituximab focused primarily on its use as salvage therapy for relapsed vitreoretinal lymphoma. In a retrospective report of eyes with relapse despite prior external beam radiotherapy, intravitreal rituximab was evaluated for response patterns, outcomes, and complications, with the authors describing successful use of the treatment in this setting 42200736May.

Across the broader rituximab literature in the same period, several studies examined systemic rituximab in immune-mediated and hematologic diseases, including autoimmune premature ovarian insufficiency, glomerular diseases, neuromyelitis optica spectrum disorder, pure red cell aplasia after hematopoietic stem cell transplantation, and membranous nephropathy 42334299Jun42170767May42224638Jun42216498May42247284Jun. These reports also explored factors associated with response, such as FCGR2A and FCGR3A variants in glomerular disease and proteinuria thresholds in PLA2R-associated membranous nephropathy 42170767May42247284Jun.

Additional publications addressed rituximab-containing regimens in lymphoma, including lenalidomide plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma and previously untreated follicular lymphoma, as well as venetoclax-rituximab combinations in chronic lymphocytic leukemia 41990300Apr41915772Mar41911073Mar. A randomized trial also evaluated antihistamine pretreatment strategies to reduce rituximab infusion-related reactions during initial infusion in non-Hodgkin lymphoma 41989666Apr.

What Changes, What Holds

1. Salvage use after prior radiotherapy remains a viable role for intravitreal rituximab
REINFORCES The new report strengthens the existing account that this agent is mainly used as local salvage or adjunctive therapy in relapsed vitreoretinal lymphoma. By describing successful treatment in eyes that had already failed external beam radiotherapy, it supports the idea that intravitreal delivery can still be useful after prior ocular irradiation rather than being limited to first-line local control. The evidence is retrospective and narrow, so it sharpens practice more than it broadens it 42200736May.

2. No new ocular role is established by the broader systemic rituximab literature
NEW DIRECTION These studies do not alter what intravitreal rituximab is understood to do, because they concern systemic rituximab in non-ocular diseases and the Overview covers no such role. Their relevance is indirect at most: they show the drug’s wider immunologic and hematologic use, but they do not add evidence for intravitreal administration, ocular efficacy, or ocular safety. For the article on intravitreal rituximab, this paragraph adds context rather than a change in the entity’s use 42334299Jun42170767May.

3. Combination-regimen data do not change the local ocular treatment account
REINFORCES The lymphoma-regimen papers likewise leave the established intravitreal story intact, because they address rituximab as part of systemic or non-ocular combination therapy rather than as an intravitreal intervention. They may matter to the broader rituximab article, but for this entity they neither challenge nor extend the baseline claim that its principal relevance is local treatment of intraocular B-cell disease. The infusion-reaction trial is methodologically useful for systemic administration, not for intravitreal use 41990300Apr41989666Apr.

Overview update candidates: salvage intravitreal use after prior radiotherapy in relapsed vitreoretinal lymphoma.

⚠️ Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.